Fintel reports that on May 5, 2026, Wedbush initiated coverage of Sionna Therapeutics (NasdaqGM:SION) with a Outperform recommendation.
Analyst Price Forecast Suggests 22.36% Upside
As of April 28, 2026, the average one-year price target for Sionna Therapeutics is $50.09/share. The forecasts range from a low of $24.24 to a high of $66.15. The average price target represents an increase of 22.36% from its latest reported closing price of $40.94 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Sionna Therapeutics is 0MM. The projected annual non-GAAP EPS is -2.43.
What is the Fund Sentiment?
There are 103 funds or institutions reporting positions in Sionna Therapeutics. This is an decrease of 42 owner(s) or 28.97% in the last quarter. Average portfolio weight of all funds dedicated to SION is 0.47%, an increase of 7.78%. Total shares owned by institutions decreased in the last three months by 4.90% to 43,814K shares. 
The put/call ratio of SION is 15.93, indicating a bearish outlook.
What are Other Shareholders Doing?
Ra Capital Management holds 9,905K shares representing 21.94% ownership of the company. In its prior filing, the firm reported owning 10,445K shares , representing a decrease of 5.45%. The firm increased its portfolio allocation in SION by 10.29% over the last quarter.
Tpg Gp A holds 6,745K shares representing 14.94% ownership of the company. No change in the last quarter.
Orbimed Advisors holds 3,562K shares representing 7.89% ownership of the company. In its prior filing, the firm reported owning 3,705K shares , representing a decrease of 4.02%. The firm increased its portfolio allocation in SION by 16.71% over the last quarter.
Viking Global Investors holds 3,195K shares representing 7.08% ownership of the company. No change in the last quarter.
Atlas Venture Life Science Advisors holds 2,996K shares representing 6.64% ownership of the company. In its prior filing, the firm reported owning 3,616K shares , representing a decrease of 20.69%.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
